Biotickr logobiotickr

Indivior Plc

The INDV-LN stock trades on London Stock Exchange
therapeuticsunited kingdommid-capschizophreniaopioid use disordersubstance use disordercannabis use disorders

Company Description

Indivior is a global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for substance use disorders and other serious mental illnesses. Our Company was founded to help tackle the opioid crisis, one of the largest and most urgent public health emergencies of our time. Our purpose is to bring science-based, life-transforming treatments to patients. We strive to help eliminate the stigma of addiction.

Drug Pipeline

Source: Indivior Plc - 20220902
Asset
Indication
Phase
AEF0117
Cannabis Use Disorder
Phase 2
 
 
 
 
 
Buprenorphine
Opioid Use Disorder
Reg/Com
 
 
 
 
 
INDV-1000
Substance Use Disorder
Preclinical
 
 
 
 
 
INDV-2000
Substance Use Disorder
Phase 1
 
 
 
 
 
RBP-6000
Opioid Use Disorder
Reg/Com
 
 
 
 
 

Conversation

0 following
Messages Image
Log in or sign up to join the conversation.
LoginSign up

0 Comments on INDV-LN stock

Newest

Trialfinder

beta

CompletedSUBLOCADE Rapid Initiation Extension Study

CompletedINDV-2000 First in Human

Not yet recruitingStudy to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Op...

RecruitingBuprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

TerminatedAn Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

Relevant Publications

beta

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled cros...

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment

Modeling buprenorphine reduction of fentanyl-induced respiratory depression

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the eff...